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apoE isoform–specific disruption of amyloid β
peptide clearance from mouse brain
Rashid Deane,1 Abhay Sagare,1 Katie Hamm,1 Margaret Parisi,1 Steven Lane,1
Mary Beth Finn,2 David M. Holtzman,2 and Berislav V. Zlokovic1
1Center

for Neurodegenerative and Vascular Brain Disorders and Frank P. Smith Laboratory for Neuroscience and Neurosurgical Research,
Department of Neurosurgery, University of Rochester Medical School, Rochester, New York, USA. 2Department of Neurology,
Hope Center for Neurological Disorders, and Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.

Neurotoxic amyloid β peptide (Aβ) accumulates in the brains of individuals with Alzheimer disease (AD). The
APOE4 allele is a major risk factor for sporadic AD and has been associated with increased brain parenchymal and vascular amyloid burden. How apoE isoforms influence Aβ accumulation in the brain has, however,
remained unclear. Here, we have shown that apoE disrupts Aβ clearance across the mouse blood-brain barrier
(BBB) in an isoform-specific manner (specifically, apoE4 had a greater disruptive effect than either apoE3 or
apoE2). Aβ binding to apoE4 redirected the rapid clearance of free Aβ40/42 from the LDL receptor–related
protein 1 (LRP1) to the VLDL receptor (VLDLR), which internalized apoE4 and Aβ-apoE4 complexes at the
BBB more slowly than LRP1. In contrast, apoE2 and apoE3 as well as Aβ-apoE2 and Aβ-apoE3 complexes were
cleared at the BBB via both VLDLR and LRP1 at a substantially faster rate than Aβ-apoE4 complexes. Astrocytesecreted lipo-apoE2, lipo-apoE3, and lipo-apoE4 as well as their complexes with Aβ were cleared at the BBB by
mechanisms similar to those of their respective lipid-poor isoforms but at 2- to 3-fold slower rates. Thus, apoE
isoforms differentially regulate Aβ clearance from the brain, and this might contribute to the effects of APOE
genotype on the disease process in both individuals with AD and animal models of AD.
Introduction
Dementia in Alzheimer disease (AD) is associated with cerebrovascular dysfunction (1, 2), accumulation of neurotoxic amyloid β
peptide (Aβ) in the wall of blood vessels and in the brain parenchyma (3–5), and intraneuronal lesions in the form of neurofibrillary
tangles (6–8). Aβ is central to AD pathology (3, 4, 8, 9–12). According to the current concept, Aβ that accumulates in the brain in AD
is likely due to its faulty clearance from the brain (10, 11, 13–15).
LDL receptor–related protein 1 (LRP1) is a major efflux transporter for Aβ at the blood-brain barrier (BBB) (5, 16, 17). Binding of Aβ
to LRP1 at the abluminal side of the BBB in vivo initiates a rapid
Aβ clearance from brain to blood via transcytosis across the BBB
(16–19). Aβ binding to LRP1 cluster IV expressed at the basolateral
side of the kidney epithelial monolayers leads to Aβ internalization and degradation (20).
apoE genotype has a significant effect on the development of
AD. apoE4 allele is a major genetic risk factor for sporadic AD,
whereas apoE2 allele decreases the risk for AD (reviewed in ref. 21).
The exact mechanism by which apoE influences the onset and progression of AD is not completely understood. By acting as an Aβ
chaperone molecule, apoE appears to influence brain Aβ metabolism, deposition, toxicity, fibril formation, and clearance (22–25).
Murine apoE and human apoE isoforms facilitate in vivo brain
Aβ fibrillogenesis in different mouse models of AD, e.g., murine
apoE>>apoE4>apoE3 (22, 23, 26–29). apoE4 also promotes the
formation of cerebral amyloid angiopathy (CAA) in a mouse
Nonstandard abbreviations used: Aβ, amyloid β peptide; APP, Aβ precursor protein; AD, Alzheimer disease; BBB, blood-brain barrier; c.p.m., counts per minute; CSF,
cerebrospinal fluid; ISF, interstitial fluid; LDLR, LDL receptor; LRP1, LDLR-related
protein 1; VLDLR, VLDL receptor.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. doi:10.1172/JCI36663.

model of AD (30). Human apoE3 and apoE4 can both substantially increase parenchymal deposition of fibrillar Aβ in a mouse
model of familial Dutch and Iowa CAA (31).
Although several studies have suggested that apoE may retain
Aβ in brain parenchyma (11), little is known about the effects of
apoE isoforms on clearance of Aβ from brain across the BBB. Here,
we report that apoE disrupts Aβ clearance at the BBB in an isoform-specific manner (e.g., apoE4>apoE3 or apoE2) by redirecting
a rapid clearance of unbound free Aβ40 and Aβ42 from LRP1 to
the VLDL receptor (VLDLR), a receptor with a substantially slower
endocytotic rate compared with LRP1 (32), which we show acts to
slowly clear apoE and Aβ-apoE complexes.
Results
First, we used our brain tissue clearance technique (16, 17, 19) to
compare the disappearance curves from brain interstitial fluid
(ISF) of 125I-radiolabeled lipid-poor recombinant human apoE
isoforms, astrocyte-derived lipo-apoE isoforms (33), unbound free
monomeric synthetic human Aβ40 and Aβ42 peptides, and complexes of various apoEs with Aβ40 and Aβ42. Different apoE and
Aβ test tracers and their complexes were microinfused into brain
ISF at equimolar concentration of 40 nM simultaneously with
14C-inulin (reference marker). Clearance was measured over a period of 30 to 300 minutes. It is of note that clearance rates of unlabeled and corresponding 125I-labeled apolipoproteins and Aβ have
been shown to be almost identical (19). Total efflux from brain ISF
of lipid-poor apoE isoforms corrected for degradation (see below)
was significantly slower than that of Aβ40 or Aβ42 (Figure 1A).
The analysis of 2 transport components contributing to total
efflux of undegraded ligands from brain indicated less efficient efflux across the BBB of apoE isoforms compared with Aβ
isoforms, whereas transport by ISF bulk flow was very slow and
similar for all test tracers studied (Figure 1B). apoE4 was cleared
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Figure 1
apoE isoform–specific clearance across the mouse BBB in vivo. (A) Time-disappearance curves of 14C-inulin (reference molecule, black) and
125I-labeled human lipid-poor apoE4 (dark green), apoE3 (light green), apoE2 (yellow green), Aβ42 (dark blue), and Aβ40 (light blue) after microinfusion of tracers mixture into brain ISF in the caudate nucleus. Test tracers were studied at 40 nM. The percentage recovery in brain was calculated
using Equation 1 (see Methods). TCA-precipitable 125I-radioactivity was used. Each point represents a single experiment. (B) Time-dependent efflux
across the BBB of 125I-labeled Aβ40, Aβ42, lipid-poor apoE2, apoE3, and apoE4 (yellow green, light green, dark green) and lipo-apoE2 (brown), lipoapoE3 (red), and lipo-apoE4 (orange) was calculated from data in Figure 1A and Equation 4 (see Methods). The ISF bulk flow for studied test tracers was calculated using Equation 2 (see Methods). (C) Relative contributions of transport across the BBB (black bars), ISF flow (white bars), and
degradation (dark gray bars) to clearance of apoE isoforms from brain and their retention in the brain (light gray bars) were studied at 40 nM concentrations and calculated from fractional coefficients given in Supplemental Table 1. Mean ± SEM; n = 11–24 mice per group for multiple-time series.
*P < 0.05, lipid-poor apoE4 versus lipid-poor apoE3 or apoE2; †P < 0.05, lipo-apoE4, lipo-apoE3, and lipo-apoE2 versus corresponding lipid-poor
apoE4, apoE2 and apoE3. ‡P < 0.05, lipo-apoE4 versus lipo-apoE3 or lipo-apoE2. (D and E) Time-appearance curves of 14C-inulin and 125I-labeled
lipid-poor apoE4, apoE3, and apoE2 (TCA-precipitable 125I-radioactivity) in the CSF (D) and plasma (E) from experiments as in A. ID, injected dose.
§P < 0.05, apoE2, apoE3, and apoE4 versus inulin; ¶P < 0.05, apoE4 versus apoE2 or apoE3. Mean ± SEM; n = 3–5 mice per group.

at a considerably slower rate across BBB compared with apoE3 or
apoE2, as indicated by the respective slopes of the radioactivity
disappearance curves at the BBB (Figure 1B). Lipidation favored
apoE retention in the brain in an isoform-specific manner, i.e.,
lipo-apoE4>lipo-apoE3 or lipo-apoE2, and thereby further diminished apoE BBB clearance compared with their respective lipidpoor isoforms (Figure 1B). Since lipo-apoE was a mixture of different size particles, i.e., 7–12 nm and 12–17 nm (33), in a separate
study, we compared clearance of different size lipo-apoE particles.
As illustrated for lipo-apoE3, there was not a significant difference in clearance from the brain between 7–12 nm and 12–17 nm
particles compared with a mixture of 7–17 nm particles (Supple

mental Figure 1; supplemental material available online with this
article; doi:10.1172/JCI36663DS1). Therefore, in all studies with
lipo-apoE, we used a mixture of apoE particles.
According to our model (see Methods), the elimination of inulin
from brain ISF (Figure 1A) reflects a passive drainage of molecules
via the ISF bulk flow, as reported (16, 17, 19). The fractional transport rate constants (k, min–1 × 103) for different apoE lipid–poor
and lipidated isoforms were calculated from 72 individual experiments (as shown in Figure 1A) by using Equations 2 and 4 (see
Methods). The rates of the total efflux, elimination via transport
across the BBB, elimination by the ISF bulk flow, and retention
in the brain corrected for degradation as well as the half-times
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Figure 2
apoE isoform–specific clearance across the
mouse BBB in vivo depends on differential
contributions of VLDLR-mediated and LRP1mediated transport. (A) 125I-labeled lipoapoE2, lipo-apoE3, and lipo-apoE4 (TCA-precipitable 125I-radioactivity) BBB clearance at
90 minutes in the presence and absence of
receptor-specific blocking antibodies against
VLDLR, LRP1, and LDLR and excess unlabeled ligands at 0.5 μM. (B) Western blot
analysis of VLDLR, LDLR, and LRP1 in brain
microvessels isolated from control, VLDLR–/–,
and LDLR–/– mice. β-actin was used as a loading control. The lanes were run on the same
gel but were noncontiguous. Representative
blots from 3 mice per group are shown. (C and
D) 125I-labeled lipo-apoE2, lipo-apoE3, and
lipo-apoE4 (TCA-precipitable 125I-radioactivity) BBB clearance at 90 minutes in VLDLR–/–
(C) and LDLR–/– mice (D) in the presence
and absence of receptor-specific antibodies
against VLDLR, LRP1, or LDLR. Values are
mean ± SEM; n = 3–5 mice per group.

for clearance and retention in the brain are given in Supplemental Table 1. Figure 1B and Supplemental Table 1 show that the
transport rate via the BBB of lipo-apoE4 was 8.3-fold, 4.9-fold, and
2.9-fold lower than that for free Aβ40, lipid-poor apoE2 or apoE3,
and apoE4, respectively, and 2.6-fold and 2.4-fold lower than for
lipo-apoE2 and lipo-apoE3, respectively. Conversely the retention
rate of free Aβ40 in the brain was the shortest, i.e., 4.1 × 10–3 min–1,
as reported (16). This was 1.7-fold faster than for Aβ42, consistent with the previous report demonstrating a 1.9-fold faster BBB
efflux rate for Aβ40 compared with Aβ42 (19). Aβ40 retention
rate was 3.8-fold and 9.5-fold less than for lipid-poor apoE2 and
apoE4, respectively, or 11.7 and 15.9 times less than for lipo-apoE2
and lipo-apoE4, respectively (Supplemental Table 1). These data
indicate that lipo-apoE4 has by far the greatest retention rate in
the brain and very slow efflux across the BBB compared with other
apoE isoforms or Aβ peptides.
During these relatively short-term transport kinetic experiments, apoE was minimally degraded in the brain ISF at 30 or
300 minutes (less than 10%), as shown by TCA-precipitation and
SDS-PAGE analyses of brain tissue supernatants after 125I-apoE2
and 125I-apoE4 microinfusion (Supplemental Figure 2, A and
B). However, there was a significant time-dependent progressive
degradation of both apoE2 and apoE4 in plasma, as shown by a
significant increase in their respective TCA nonprecipitable fractions (Supplemental Figure 2C), indicating metabolism either
during transport across the BBB and/or during systemic clearance in the circulation. There was also very low degradation of
lipo-apoE isoforms ranging from 10%–15%, as indicated by the
TCA-precipitation analysis of brain supernatants after 125I–lipoapoE2 and 125I–lipo-apoE4 microinfusion (Supplemental Figure

2D). The relative contributions to clearance of apoE isoforms by
transport across the BBB, ISF flow and degradation, and retention in the brain of undegraded and uncleared apoE ligands indicated a reciprocal relationship between transport across the BBB
and retention of apoE ligands in the brain, namely, the higher the
BBB transport, the lower the retention in the brain and vice versa
(Figure 1C). The slow clearance via the ISF flow and low rates of
degradation were similar between different lipid-poor and lipoapoE isoforms and did not influence significantly BBB transport
or retention. This analysis importantly suggests that a failure in
effective removal across the BBB is a key to high retention of lipoapoE4 in the brain compared with apoE3 or apoE2, which exhibit
moderate transport across the BBB.
All 3 lipid-poor apoE isoforms (Figure 1D) as well as lipo-apoE
isoforms (not shown) appeared in the cerebrospinal fluid (CSF)
with a pattern comparable to that of inulin, a reference molecule
that is cleared from brain ISF into CSF by passive diffusion via
ISF bulk flow (16). Therefore, apoE clearance from brain ISF to
CSF did not exhibit an isoform-specific effect. In contrast, apoE
isoforms microinjected into brain ISF appeared in plasma with
a significantly different pattern, i.e., apoE2 and apoE3 greater
than apoE4 (TCA precipitable), compared with almost negligible levels of inulin at the corresponding time points between
100 and 300 minutes (Figure 1E). These data confirmed that
(a) the reference molecule inulin is not transported across the
BBB, as shown previously (16, 19, 34), (b) there is an in vivo
transcytosis of apoE2 and apoE3 across the BBB into the blood,
and (c) apoE4 transport across the BBB from brain to blood is
negligible. It is of note that the time-appearance curves of apoE
isoforms in plasma cannot be used to estimate total recovery of
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Figure 3
apoE isoforms disrupt Aβ clearance across the mouse BBB in vivo (apoE4>apoE3 or apoE2) by redirecting differentially redirecting transport of
Aβ-apoE complexes from LRP1 to VLDLR. 125I-labeled apoE-Aβ complexes (40 nM) and 14C-inulin were microinfused into brain ISF and clearance
determined at 90 minutes. 125I-label was either on Aβ40 and Aβ42 or on apoE2 and apoE4. (A) FPLC purification of apoE2-Aβ40. Upper panel
shows dot blots of Aβ40-apoE2 and free Aβ peaks with Aβ-specific (6E10) and apoE-specific (3D12) antibodies. (B and C) BBB clearance of
Aβ40 (B) and Aβ42 (C) with and without an LRP1-specific blocking antibody and of their complexes with lipid-poor and lipo-apoE2 and lipid-poor
and lipo-apoE4, as indicated. (D) Clearance of Aβ40 and Aβ42 by transport across the BBB (black bars), ISF flow (white bars) and degradation
(light gray bars) and retention in the brain (dark gray bars) studied from different 125I-Aβ40-apoE and Aβ42-apoE complexes at 40 nM and compared with free Aβ40 or Aβ42. 125I-label was on Aβ. Clearance and retention were calculated from fractional coefficients using Equations 2, 5, and
6 (see Methods). Mean ± SEM, n = 5–6 mice per group in a single time-point series. *P < 0.05, Aβ40-apoE2 and Aβ40-apoE4 versus Aβ40 and
Aβ42–lipo-apoE2, Aβ42–lipo-apoE3, and Aβ42–lipo-apoE4 versus Aβ42; †P < 0.05, Aβ40-apoE4 versus Aβ40-apoE2 and Aβ42–lipo-apoE4 versus Aβ42–lipo-apoE3 or Aβ42–lipo-apoE2; ‡P < 0.05, Aβ40–lipo-apoE2 and Aβ40–lipo-apoE4 versus Aβ40-apoE2 and Aβ40-apoE4; §P < 0.05,
Aβ40–lipo-apoE4 versus Aβ40–lipo-apoE3 or Aβ40–lipo-apoE2. (E) BBB clearance of 125I-Aβ40–lipo-apoE2 and 125I-Aβ40–lipo-apoE3 in control
mice with and without blocking antibodies to VLDLR, LRP1, and LDLR. (F and G) BBB clearance of 125I-Aβ40–lipo-apoE2 (F) and 125I-Aβ42–lipoapoE4 complexes (G) in control (white bars), VLDLR–/– (gray bars), and RAP–/– (black bars) mice with and without blocking antibodies to LRP1,
VLDLR, and/or LDLR. Mean ± SEM; n = 4–6 mice per group.

apoE ligands in plasma because apoE entering the plasma compartment is continuously removed from the plasma by systemic
clearance via liver, kidney, and other organs (19). Therefore, the
areas under curves in Figure 1E underestimate apoE recovery


in plasma. Similarly, the time-appearance curves of apoE in the
CSF are influenced by the CSF’s rapid turnover rate, which continuously clears molecules into blood by nonspecific absorption
across the arachnoid granulations (2).
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Figure 4
Isoform-specific lipid-poor apoE clearance at the abluminal surface of mouse brain capillaries in vitro is regulated
by differential internalization rates of VLDLR and LRP1.
(A) Specific binding of 125I-labeled lipid-poor apoE2,
apoE3, and apoE4 (2 nM, TCA-precipitable 125I-radioactivity) by brain microvessels studied for a period of
30 minutes at 4°C with and without excess of unlabeled
ligand at 0.5 μM. (B–D) Time-dependent internalization of
lipid-poor 125I-apoE2 (B), 125I-apoE3 (C), and 125I-apoE4
(D) on the abluminal surface of brain microvessels in the
presence of receptor-specific blocking antibodies to LRP1
and VLDLR and excess of unlabeled ligand at 0.5 μM.

Since apoE binds to different lipoprotein receptors, e.g., VLDLR,
LDL receptor (LDLR), and LRP1 (35) that are expressed at the
BBB and may have roles in signaling, endocytosis, and/or transcytosis of their respective ligands (36), we next used lipoprotein
receptor–specific antibodies (Fab2) against VLDLR, LDLR, and
LRP1 to determine whether blocking these receptors influences
the efflux of apoE isoforms across the BBB. Specific receptor–
blocking antibodies were infused in the ISF 15 minutes prior to
tracer infusion and then simultaneously with the tracer mixture
containing test apolipoproteins at their physiologic CSF concentration of 40 nM. Figure 2A shows that anti-VLDLR– and antiLRP1–blocking antibodies inhibited the BBB efflux of lipo-apoE2
and lipo-apoE3 by 50% and 30%, and 58% and 40%, respectively,
while anti-LDLR did not have an effect. A combination of antiVLDLR and anti-LRP1 almost completely (~85%) inhibited apoE2
efflux at the BBB, whereas adding anti-LDLR to anti-VLDLR did
not have an effect on apoE2 efflux inhibition greater than that of
adding anti-VLDLR alone. The BBB clearance of both lipo-apoE2
and lipo-apoE3 was almost completely inhibited (>90%) by excess
unlabeled ligand. These data suggest that VLDLR and LRP1 are
likely to have a role in mediating apoE2 and apoE3 efflux at the
BBB, whereas a nonspecific clearance accounts for less than 10%
of the specific receptor–mediated clearance. In contrast, blocking LRP1 or LDLR did not have an effect on lipo-apoE4 efflux at
the BBB (Figure 2A), whereas blocking VLDLR resulted in more
than 85% inhibition. Adding anti-LRP1 or anti-LDLR to antiVLDLR did not result in greater inhibition of lipo-apoE4 efflux
compared with inhibition seen with adding anti-VLDLR alone.
As with apoE3 and apoE2, excess unlabeled ligand inhibited
125I–lipo-apoE4 clearance by more than 85%. These data suggest
that VLDLR is a major receptor mediating lipo-apoE4 efflux at
the BBB, whereas LRP1 is not involved. A minor portion (~10%)
of BBB apoE4 clearance was by a nonspecific unsaturable transport, as with apoE2 and apoE3. A similar pattern for the receptors’ involvement was obtained with lipid-poor apoE2 and apoE4

(Supplemental Figure 3), suggesting VLDLR and LRP1 are
required for efflux of apoE2 across the BBB, whereas VLDLR, but
not LRP1, mediates very slow efflux of apoE4.
The involvement of receptors was next tested using mice with
specific deletions of the VLDLR and LDLR genes. First, we showed
that deletion of the VLDLR gene does not alter the expression of
LDLR and LRP1 proteins in brain capillaries and, similarly, that
LDLR deletion does not alter the expression of VLDLR and LRP1
in brain capillaries (Figure 2B). Deletion of the VLDLR gene, however, reduced clearance of lipo-apoE2 and lipo-apoE3 by about
60% and clearance of lipo-apoE4 at the BBB by more than 80%
(Figure 2C). Addition of an LRP1-specific blocking antibody led
to an approximately 90% inhibition of apoE2 and apoE3 BBB
efflux in VLDLR–/– mice compared with values in the wild-type
mice (Figure 2C) but did not have an effect on lipo-apoE4 efflux
(Figure 2C). These data confirmed that VLDLR is a major receptor
for apoE4 clearance from brain, whereas both LRP1 and VLDLR
clear apoE2 and apoE3 at the BBB. We performed a similar experiment in LDLR–/– mice and found that deletion of LDLR did not
affect either lipo-apoE2 or lipo-apoE4 efflux at the BBB (Figure
2D). The addition of VLDLR and LRP1 antibodies decreased efflux
of lipo-apoE2 in LDLR–/– mice by 58% and 32%, thus confirming
the role of these 2 receptors in apoE2 clearance. Conversely, blocking LRP1 did not have any effect on lipo-apoE4 efflux in LDLR–/–
mice, whereas VLDLR-specific antibodies diminished efflux of
lipo-apoE4 by 85%, confirming that VLDLR is a major receptor
required for slow apoE4 clearance at the BBB.
Since apoE binds Aβ with high affinity and is known to be
an Aβ-binding protein (21), we next determined whether binding of Aβ to apoE alters Aβ clearance across the BBB from preformed apoE-Aβ complexes. The formation of apoE2-Aβ40 and
apoE4-Aβ40 complexes was demonstrated by 4%–20% Tris-glycine
nondenaturing gradient gel electrophoresis for lipidated complexes and 10%–20% Tris-tricine native PAGE analysis for lipidpoor complexes (not shown), as we reported previously (33, 37).
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Figure 5
Isoform-specific lipo-apoE clearance at the abluminal surface of mouse brain capillaries in vitro is regulated by differential internalization
rates of VLDLR and LRP1. (A) Binding of 125I-labeled lipo-apoE2 and lipo-apoE4 (2 nM, TCA-precipitable 125I-radioactivity) to isolated brain
microvessels. (B and C) Time-dependent internalization of 125I-labeled lipo-apoE2 (B) and lipo-apoE4 (C) in the presence of receptor-specific blocking antibodies against VLDLR and LRP1 and excess of unlabeled ligand at 0.5 μM. (D) Binding of 125I-labeled lipo-apoE2 to brain
microvessels from control, VLDLR–/–, and LDLR–/– mice. (E–G) Internalization of 125I-labeled lipo-apoE2 (E), lipo-apoE3 (F), and lipo-apoE4
(G) at the abluminal surface of brain microvessels from control (white bars) and VLDLR–/– (black bars) mice studied for a period of 30 minutes.
Means ± SEM, n = 3 experiments per group.

Size exclusion chromatography was used to remove excess free
Aβ from all apoE-Aβ preparations. For example, in the case of
a lipid-poor apoE2-Aβ40 complex, a peak eluting at 29 minutes
that was positive for both apoE (3D12 antibody) and Aβ (6E10)
represented an Aβ40-apoE complex (Figure 3A), whereas excess
free Aβ eluted later with a peak at 32 minutes that was positive
only for 6E10 (Aβ) and negative for 3D12 (apoE), indicating free
Aβ. We then compared clearance of free Aβ40 versus Aβ40-apoE
complexes with either apoE2 or apoE4 at equimolar physiologic
CSF concentrations (40 nM). In contrast to free Aβ40, Aβ-apoE2
or Aβ-apoE4 complex was not cleared significantly at the BBB
within 30 minutes (not shown). At 90 minutes, more than 85%
of free Aβ40 was eliminated at the BBB exclusively through an
LRP1-mediated transport (i.e., blockade or lack of VLDLR and
LDLR did not influence Aβ efflux), as reported (16, 17, 19). This
clearance was much greater than the approximately 38% and 24%
clearance of Aβ40 seen when it was complexed with lipid-poor
apoE2 and apoE4, respectively (Figure 3B). The same results were
obtained regardless of whether the label (125I) was on apoE or Aβ.
apoE lipidation further diminished the BBB efflux of Aβ40 to 15%
and 9% via apoE2 and apoE4, respectively. Even more pronounced
differences were obtained between Aβ42-apoE2 and Aβ42-apoE4
complexes (Figure 3C). For example, only 25% and 12% of Aβ42
was cleared via lipid-poor apoE2 and apoE4, respectively, whereas
9% and 3% of Aβ42 was cleared by lipo-apoE2 and lipo-apoE4,
respectively, compared with 38% as seen for free unbound Aβ42.
As we reported, there was minimal degradation of free monomeric Aβ40 or Aβ42 microinjected into the brain ISF (16, 17). In


these relatively short-term kinetic studies and at apoE levels corresponding to physiological concentrations of apoE in the CSF,
degradation of Ab was not significantly influenced by its binding
to either apoE2, apoE3, or apoE4 (either lipid poor or lipidated)
at 30 and 300 minutes. Degradation of both Aβ40 and Aβ42 was
approximately 10% (Supplemental Figure 2, E and F; Figure 3D).
Figure 3 D shows the relative contributions of transport across
the BBB, ISF flow, and degradation to the clearance of Aβ40 and
Aβ42 when in complex with apoE2, apoE3, or apoE4 isoforms
compared with free Aβ40 and Aβ2. The data indicate that binding
of Aβ to apoE inhibits rapid efflux of Aβ40 and Aβ42 across the
BBB in an isoform-specific fashion, i.e., Aβ clearance was inhibited to the greatest degree when in complex with apoE4 compared
with clearance of Aβ-apoE3 and Aβ-apoE2, and this inhibition was
significantly enhanced by apoE lipidation. There was a reciprocal
relationship between reductions in BBB transport and accumulations of undegraded Aβ-apoE complexes in the brain, whereas the
ISF flow and degradation were similar for all studied complexes.
Aβ40 and Aβ42 efflux across the BBB was inhibited to the greatest degree when either was complexed with lipo-apoE4; efflux was
3-fold lower for such complexes compared with Aβ complexed
with lipo-apoE3 or lipo-apoE.
We next used a panel of lipoprotein receptor–specific antibodies
to determine whether the same receptors mediating apoE2, apoE3,
and apoE4 efflux at the BBB are required for efflux of Aβ complexes
with apoE2, apoE3, and apoE4. Clearance of 125I-Aβ40–lipo-apoE2
and 125I-Aβ40–lipo-apoE3 complexes at the BBB was inhibited by
both VLDLR and LRP1 antibodies (Figure 3E); the involvement of
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Figure 6
apoE isoform–specific inhibition (apoE4>apoE3 and
apoE2) of Aβ internalization
at the abluminal surface of
mouse brain capillaries in vitro
is mediated by VLDLR. (A)
Specific binding of 125I-labeled
Aβ40 and Aβ42 complexes
with apoE2 and apoE4 at 4°C
in the absence and presence
of receptor-specific blocking
antibodies to VLDLR, LDLR,
or LRP1 and excess unlabeled ligand at 0.5 μM. (B)
Internalization of 125I-Aβ40 in
the absence and presence of
receptor-specific blocking antibodies against LRP1 and of
125I-labeled Aβ40–lipo-apoE2,
Aβ40–lipo-apoE3, and Aβ40–
lipo-apoE4 complexes for a
period of 30 minutes. (C) Internalization of 125I-labeled Aβ40,
Aβ40–lipo-apoE2, Aβ40–lipoapoE3, and Aβ40–lipo-apoE4
in the absence and presence
of receptor-specific blocking
antibodies against LRP1 and
VLDLR. Means ± SEM; n = 3–5
experiments per group.

VLDLR was confirmed in VLDLR–/– mice, which exhibited a 60%
reduction in 125I-Aβ40–lipo-apoE2 clearance compared with littermate controls (Figure 3F). As seen with apoE2, anti-LRP1 inhibited
the efflux of 125I-Aβ40–lipo-apoE2 from brains in VLDLR–/– mice by
an additional 30%. In contrast, 125I-Aβ42–lipo-apoE4 BBB clearance
was inhibited by more than 80% in VLDLR–/– mice compared with
controls and was not affected by an LRP1-specific antibody (Figure
3G). Efflux of 125I-Aβ40–lipo-apoE2 was significantly reduced (by
approximately 40%) in RAP–/– mice (Figure 3F), a functional LRP1
knockout with severely depleted (~80%) LRP1 levels at the BBB
(17). In contrast, 125I-Aβ40–lipo-apoE4 efflux at the BBB was not
affected in RAP–/– mice (Figure 3G). These experiments confirm the
results obtained with LRP1-specific blocking antibodies.
We then asked whether isoform-specific differences in apoE
clearance across the BBB in vivo may reflect differences among the
internalization rates of different apoE isoforms by their respective
lipoprotein receptors at the abluminal side of the BBB. To address
this question, we used isolated mouse brain microvessels as a
model, as reported (17). Lipid-poor apoE bound to the abluminal
surfaces of isolated mouse brain microvessels in an isoform-specific manner, e.g., apoE2>apoE3>apoE4, and was almost displaced
by excess unlabeled ligand (Figure 4A). Receptor-bound apoE2
and apoE3 were internalized by endocytosis with a t1/2 of about

3.9 ± 0.3 and 3.6 ± 0.4 minutes, respectively (Figure 4, B and C).
Specific lipoprotein receptor–blocking antibodies were then used
to identify the respective contributions of VLDLR and LRP1 in
apoE2 and apoE3 endocytosis. First, we showed that apoE2 internalization was inhibited completely when both VLDLR and LRP1
were blocked as well as when there was excess unlabeled apoE2
(Figure 4B). When VLDLR only was blocked, apoE2 internalization reflected endocytosis via LRP1 that was extremely rapid,
with a t1/2 of less than 30 seconds, consistent with the previously
shown rapid endocytic rate of LRP1 (17, 32). In contrast, when
LRP1 was blocked, the apoE2 internalization was much slower,
with a t1/2 of 8.5 ± 1.5 minutes. This is consistent with a previous
study demonstrating that VLDLR has the slowest internalization
rate of all lipoprotein receptors (32). Similar results suggesting a
rapid efflux component via LRP1 and a slow efflux component
via VLDLR were obtained for apoE3 (Figure 4C). We next repeated
the same experiment with apoE4 and found that its internalization rate was much slower than that of apoE2 and apoE3, with a
t1/2 of 8.7 ± 1.5 minutes (Figure 4D). Blockade of VLDLR resulted
in almost complete inhibition of apoE4 internalization, whereas
blockade of LRP1 did not affect apoE4 endocytosis, consistent
with our in vivo findings. LRP1- and VLDLR-specific antibodies together did not have a greater effect on inhibition of apoE4
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internalization than VLDLR antibody alone. Therefore, in the
presence of an LRP1 antibody, apoE4 endocytosis was mediated
via VLDLR, with a t1/2 of 8.9 ± 1.3 minutes, which was comparable
to a t1/2 of VLDLR-mediated internalization for the Aβ-apoE2 and
Aβ-apoE3 complexes. These results suggest that LRP1 contributed
to a substantially faster internalization rate at the BBB of apoE2
and apoE3 compared with apoE4, which was internalized slowly
by VLDLR only. During these short-term kinetic internalization
studies, there was low degradation (<5%) of apoE2 and apoE4, as
determined by their respective TCA nonprecipitable fractions in
brain vessel lysates and in the incubation medium over the studied
short periods of time (not shown).
Next, we used astrocyte-derived lipo-apoE particles to determine whether the same internalization receptor requirements
held as for the lipid-poor apoE isoforms. There was again an
isoform-specific difference in lipo-apoE2 versus lipo-apoE4
binding (Figure 5A). The internalization rate of lipo-apoE2 was
significantly faster than that of lipo-apoE4 (Figure 5, B and C),
with the respective t1/2 values of 3.9 ± 0.4 minutes and 8.4 ± 1.4
minutes, which were comparable to the t1/2 values of their lipidpoor counterparts (see above). A combination of VLDLR- and
LRP1-specific blocking antibodies resulted in complete inhibition of lipo-apoE2 internalization, whereas inhibition of VLDLR
revealed a fast LRP1 component of lipo-apoE2 internalization,
with a t1/2 of less than 30 seconds (Figure 5B). Internalization
of lipo-apoE4 was almost completely blocked with a VLDLRspecific antibody, revealing no fast LRP1 component, as seen
for lipid-poor apoE4 (Figure 5C). By using isolated capillaries
from VLDLR–/– and LDLR–/– mice, we confirmed that LDLR was
not involved in uptake of lipo-apoE2 or lipo-apoE4 (not shown),
whereas deletion of VLDLR resulted in a greater than 60% reduction in apoE2 binding (Figure 5D) and internalization (Figure
5E) as well as in an approximately 60% inhibition in lipo-apoE3
internalization (Figure 5F). In VLDLR–/– mice, the internalization of lipo-apoE2 or lipo-apoE3 was inhibited up to 90% by
addition of an LRP1-specific antibody (Figure 5, E and F). Internalization of lipo-apoE4 was inhibited by approximately 80% in
VLDLR–/– mice (Figure 5G).
Binding and internalization of apoE-Aβ complexes at the abluminal surface of brain microvessels was next studied using the
fast protein liquid chromatography–purified (FPLC-purified)
apoE2-Aβ40 and apoE4-Aβ40 complexes as above. Aβ40-apoE2
and Aβ42-apoE2 complexes bound to both VLDLR and LRP1,
whereas Aβ40-apoE4 and Aβ42-apoE4 complexes bound only
to VLDLR, not to LRP1, as shown with the lipoprotein receptor–
specific blocking antibodies (Figure 6A). Binding of radiolabeled
complexes was inhibited by more than 90% by excess unlabeled
ligand. The internalization rate of free Aβ40 was rapid, i.e., t1/2 was
less than 30 seconds and was completely inhibited by an LRP1specific antibody, as reported (17). The internalization rates of
Aβ40 complexes with lipo-apoE2 and lipo-apoE3 were comparable but substantially lower than for Aβ40 alone, as indicated
by their respective internalization curves (Figure 6B). There was a
clear isoform-specific effect, i.e., lipo-apoE2 and lipo-apoE3 internalized Aβ40 at rates significantly higher than lipo-apoE4 (Figure
6B). As shown in Figure 6C, both VLDLR and LRP1 were involved
in endocytosis of Aβ40 via lipo-apoE2 and lipo-apoE3, whereas
VLDLR was the key receptor for internalization of Aβ40–lipoapoE4 complex. LRP1-dependent internalization of Aβ40 was
shown by comparison.


Discussion
APOE genotype is the only established genetic risk factor for
late-onset sporadic AD with an isoform-specific risk profile of
apoE4>apoE3>apoE2 (21, 38, 39). Still, it remains unclear how
apoE4 accelerates and apoE2 retards AD pathology to influence
cognitive decline. A number of experimental studies have demonstrated that apoE critically regulates the fate of Aβ in the brain.
For example, studies in Aβ precursor protein (APP-expressing)
mice have suggested that deletion of mouse apoE gene inhibits
development of fibrillar amyloid plaques (26). On the other hand,
expression of human apoE isoforms in these mice resulted in isoform-dependent and gene-dose–dependent delay in the onset of
plaque deposition and decrease in amyloid burden (23). These
studies suggest that apoE may regulate in vivo fibrillization of Aβ
as well as the levels of soluble Aβ in the brain in an isoform-specific fashion, but the exact molecular mechanism or mechanisms
have not been identified.
The present study demonstrates that apoE disrupts clearance of Aβ from brain ISF in an isoform-specific fashion (e.g.,
apoE4>apoE3 and apoE2). apoE4 shifted BBB efflux of Aβ completely from LRP1-mediated rapid brain capillary transcytosis
(16, 17) to a very slow interaction of Aβ-apoE complexes, with
VLDLR at the abluminal side of the BBB, resulting in poor
Aβ clearance of apoE-Aβ complexes from brain. Lipo-apoE4
increased brain retention of Aβ40 and Aβ42 complexed to
apoE4 in mice by 15- and 9-fold, respectively, compared with
the unbound peptides. In contrast, apoE2 and apoE3 only moderately inhibited Aβ clearance due to their ability to interact at
least partially with LRP1 in addition to VLDLR. Based on the
present findings, one may speculate that the virtual blockade of
fibrillar Aβ deposition, as seen in apoE-null mice crossed with
APP transgenics (26), may at least in part be due to an improved
Aβ clearance from brain directly related to a loss of apoE-mediated Aβ retention. Human isoform–specific differences in Aβ
accumulation in APP mice crossed with human apoE transgenics and knockin mice on mouse apoE-null background (i.e.,
apoE4>apoE3>apoE2) (22, 23, 27, 28) might reflect apoE isoform–specific disruption of free Aβ clearance, which is significantly greater with apoE4 than with apoE3 and apoE2. The reason that Aβ deposition occurs earlier in APP transgenic mice on
a mouse apoE-null background versus mice expressing human
apoE (22, 28, 30) is not clear. However, it must be noted that
fibrillar Aβ or true amyloid deposition is delayed to the greatest
extent in the absence of apoE, consistent with human apoE isoform–mediated retention of an apoE-bound Aβ pool leading to
earlier Aβ fibril formation in an isoform-specific fashion.
In addition to mediating endocytosis and signaling in the vascular wall (40), the lipoprotein receptors mediate transcytosis of
their ligands across the BBB (36). For example, LRP2 mediates
transport of apoJ and apoJ-Aβ complexes across the BBB (19, 41),
LDLR may transport LDL (42) and LDL apoproteins conjugated
to nanoparticles encapsulating pharmaceuticals (43) across the
BBB, and LRP1 mediates clearance of unbound Aβ across the BBB
(16, 17). Earlier work indicated limited BBB permeability to circulating lipid-poor apoE2, apoE3, and apoE4 (37), supporting the
concept that apoE in blood and brain are regulated independently
(44, 45). Nevertheless, the observed differences in Aβ efflux at the
BBB by apoE isoforms may contribute to isoform-specific apoE
control of Aβ levels in the brain, which in turn may influence the
development of Aβ pathology in AD models and AD.
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Our findings showing that VLDLR internalizes Aβ-apoE2,
Aβ-apoE3, or Aβ-apoE4 complexes at the BBB with a t1/2 that is more
than 20-fold shorter than with LRP1-mediated internalization of
Aβ-apoE2, Aβ-apoE3, or Aβ is consistent with an earlier report
showing that the endocytotic rate of VLDLR is approximately
25-fold slower than that of LRP1 (32). While there have been
numerous studies on the interaction of apoE with LDL receptor
family members, only a few compare apoE isoform–binding affinities to lipoprotein receptors using the same methods. Recently,
by using a solid-phase binding assay, surface plasmon resonance
(SPR), and cell uptake experiments, it has been shown that VLDLR
does not discriminate between the apoE isoforms and binds and
internalizes lipid-free apoE2, apoE3, and apoE4 as well as their
corresponding lipidated isoforms (46), which is consistent with
the present findings. Although it has been reported that LDLR
shows a marked preference for lipo-apoE3 and lipo-apoE4 and
binds apoE2 isoform poorly (47), our study revealed that lipidfree or lipo-apoE isoforms do not use LDLR as an efflux receptor
at the BBB. This finding is consistent with a concept that LDLR at
the BBB acts mainly as an influx but not efflux receptor for LDL
particles, thus mediating transport of its ligands in the direction
from blood to brain but not from brain to blood (42, 43). However,
deletion of LDLR elevates brain and CSF apoE3 and apoE4 but not
apoE2 in human apoE-knockin mice (48), suggesting that LDLR
plays an important role in apoE clearance in nonvascular brain
cells (i.e., astrocytes, microglia, neurons).
Earlier binding studies with LRP1 suggested a requirement for
apoE-enriched remnant particles or β-migrating VLDL particles
(49). A more recent study has demonstrated that LRP1 binds lipoapoE isoforms with greater affinity than lipid-free isoforms but
does not discriminate between lipo-apoE2, lipo-apoE3, and lipoapoE4 (46). Others have shown that LRP1 mediates cellular uptake
of lipid-poor apoE isoforms in fibroblasts (50) and that lipid-poor
apoE3 binds to immobilized soluble LRP1 with higher affinity than
lipid-free apoE4 (51), although apoE3 exhibited much lower affinity
for sLRP1 compared with Aβ. The differences among various studies might result from differences in apoE preparations. Our present
findings suggest that LRP1 mediates BBB clearance of both lipidpoor and lipo-apoE2 and lipo-apoE3 and of their complexes with Aβ
but not apoE4. The difference between a previous study suggesting
binding of lipo-apoE4 to LRP1 (46) and the current study indicating
insignificant apoE4 binding to LRP1 could be due to use of different
forms of lipo-apoE particles as, for example, those secreted by primary astrocytes as in the present study (33) versus plasma-derived
and/or might reflect differences between in vitro binding assays
compared with the lack of interaction with LRP1, as seen in situ at
the abluminal side of the mouse BBB. It is also possible that apoE4
has greater affinity to bind to LDLR on cells in the brain or heparan
sulfate proteoglycans in the extracellular matrix, which precludes its
effective interaction with the clearance LRP1 receptor at the BBB.
Lipidation greatly reduced the amount of apoE and its complexes with Aβ that were cleared at the BBB. Although it did not
significantly change the t1/2 for ligand internalization, lipo-apoE
interacts with Aβ in vitro with a higher affinity than its lipidpoor counterparts (52–54). Thus, it is likely that lipidation critically influences both Aβ transport and metabolism. It has been
reported that apoE facilitates Aβ degradation by astrocytes (55,
56) and by microglia (57). Recently, it has been demonstrated
that endocytic degradation of Aβ peptides within microglia by
neprilysin and related enzymes is dramatically enhanced by apoE

as well as Aβ degradation by insulin-degrading enzyme (25). The
capacity of apoE to promote degradation was isoform dependent
(e.g., apoE4<apoE3 or apoE2) and enhanced by expression of
lipo-apoE. In contrast to studies showing apoE-mediated cellular
clearance of Aβ by astrocytes and microglia (25, 55–57), a lack
of significant cellular Aβ degradation from apoE-Aβ complexes
in the present study may reflect a relatively smaller role for cellular clearance by astrocytes and microglia of soluble apoE and
Aβ when studied in vivo, as detected by microdialysis or in this
type of brain clearance study, as we reported (17–19, 34, 58). The
isoform-specific brain retention of apoE and apoE-Aβ complexes
(apoE4>apoE2 or apoE3) found in the present study might contribute to apoE isoform–specific effects on Aβ cytotoxicity (59),
aggregation, and fibrillogenesis (23, 29) as well as apoE self aggregation and neurotoxicity (60).
In summary, our findings suggest that the differences in Aβ
clearance from brain by different apoE isoforms might contribute
to the observed effects of apoE genotype on the disease process in
AD and AD models. As suggested, disrupting Aβ interaction with
apoE holds a therapeutic potential for AD (61–64). Considering
the present results, such therapies should be able to enhance Aβ
clearance from brain.
Methods
Aβ peptides. Aβ40 and Aβ42 were obtained from the W.M. Keck Foundation
Biotechnology Resource Laboratory (Yale University, New Haven Connecticut, USA). They were synthesized by solid-phase F-moc (9-fluorenylmethoxycarbonyl) amino acid chemistry, purified by reverse-phase HPLC, and structurally characterized. Lyophilized peptides were kept at –80°C until used.
Proteins. Recombinant lipid-poor human apoE2, apoE3, and apoE4
isoforms from baculovirus-transfected Sf9 cells were purchased from
Invitrogen. Lipo-apoE2, lipo-apoE3, and lipo-apoE4 isoforms were prepared and purified from conditioned medium of immortalized mouse
astrocytes derived from apoE2-, apoE3-, and apoE4-knockin mice, as previously described (33). These particles were similar in size and cholesterol
content to those secreted by primary astrocytes and bind Aβ peptides in
physiological buffers (33).
Antibodies. We used polyclonal goat receptor–specific blocking antibodies raised against the extracellular domain of LDLR (AF2255; R&D
Systems), VLDLR (AF2258; R&D Systems), and LRP1 (N20; Santa Cruz
Biotechnology Inc.).
Radioiodination. Aβ was iodinated with 125I using the lactoperoxidase
method (65). The resulting components were resolved by HPLC and the
purity analyzed by MALDI-TOF mass spectrometry, as we reported (66). In
our studies, we used only reduced monoidinated Aβ peak (specific activity
~60 μCi/μg), as confirmed by MALDI-TOF mass spectrometry analysis, as
reported (66). Lipid-poor and lipo-apoE was radiolabeled by IODO-GEN
(Thermo Scientific) to a specific activity of 9–12 μCi/μg. Free iodide was
removed from radiolabeled apoE preparations by gel filtration.
Formation of Aβ-apoE complexes with monomeric Aβ species. Lipidated and lipidpoor 125I-labeled apoE2 and apoE4 complexes with synthetic human Aβ40
and Aβ42 were prepared as we described (36), except the ratio of Aβ to apoE
was 40 to 1. Complexes were purified by fast flow size-exclusion chromatography (FPLC) to remove excess free Aβ. Formation of complexes between lipoapoE and lipid-poor apoE isoforms with Aβ isoforms and complete removal
of excess free Aβ were verified as we reported by nondenaturing 4%–20% Trisglycine polyacrylamide gel (Invitrogen) (33) and 10%–20% Tris-tricine polyacrylamide gel (Bio-Rad), respectively, followed by Western blot analysis for
apoE and Aβ (33). 125I-labeled Aβ40 or Aβ42 complexes with unlabeled apoE2
and apoE4 were also prepared in the same way as described above.

The Journal of Clinical Investigation

http://www.jci.org



Downloaded on August 16, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/36663

research article
Brain clearance studies. Male mice on a C57BL/6 background weighing
25–27 g and 2 to 3 months old were obtained from The Jackson Laboratory. Mice were kept under standard housing conditions and feeding schedules until the experimental procedures were performed. All studies were
performed according to the NIH guidelines using a protocol approved by
the University of Rochester Committee on Animal Resources. In brief, a
stainless steel guide cannula was implanted stereotaxically into the right
caudate putamen of anesthetized mice (100 mg/kg ketamine and 10 mg/kg
xylazine i.p.) with the cannula tip coordinates 0.9 mm anterior and 1.9 mm
lateral to the bregma and 2.9 mm below the surface of the brain. Clearance studies were performed after animals recovered from surgery. The
experiments were performed before substantial chronic process occurred,
as assessed by histological analysis of tissue, i.e., negative staining for astrocytes (glial fibrillar acidic protein) and activated microglia (antiphosphotyrosine), but allowed time for BBB repair for large molecules, as reported
previously (17, 19, 34, 58).
Injection of tracers mixture. The amount of injected tracers was accurately
determined using a micrometer to measure the linear displacement of the
syringe plunger in the precalibrated microsyringe. Mock CSF (0.5 μl) containing 125I-labeled test-tracers Aβ (monomer), apoE (lipid poor or lipidated), or Aβ-apoE complex together with 14C-inulin (reference molecule) was
microinfused into brain ISF over 5 minutes. When the effects of different
unlabeled molecular reagents were tested, they were injected 15 minutes
prior to radiolabeled ligands and then simultaneously with radiolabeled
ligands, as described (17).
Tissue sampling. At the end of the experiments, brain, blood, and CSF
were sampled and prepared for radioactivity analysis and TCA and SDSPAGE analyses to determine the molecular forms of test tracers (16, 34).
Our earlier studies with 125I-labeled Aβ have demonstrated that both radiolabeled Aβ40 and Aβ42 remain mainly intact in brain ISF (>95%) within
30–300 minutes of in vivo clearance studies (16) as well as during shortterm kinetic clearance studies in vitro on brain capillaries (17). In the present study, we confirmed previous findings indicating that molecular forms
of transport of 125I-labeled Aβ and apolipoproteins within 30–300 minutes
of clearance studies remained mainly in their original form of intact molecules, as injected in the CNS.
Calculations of clearance rates. All calculations of clearance parameters were
as reported (16, 17, 19). In brief, the percentage of radioactivity of test ligand
remaining in the brain after microinfusion was determined as follows:
% recovery in brain = 100 × (Nb/Ni) (Equation 1)
where Nb is the radioactivity of undegraded test ligand remaining in the
brain at the end of the experiment and Ni is the radioactivity injected into
the brain ISF, i.e., the disintegrations per minute (d.p.m.) for 14C-inulin
and the counts per minute (c.p.m.) for TCA-precipitable 125I-radioactivity
corrected for degradation were used. Inulin was studied as a metabolically
inert polar molecule (reference) that is neither transported across the BBB
nor retained by the brain; its clearance rate provides a measure of the ISF
bulk flow as reported (16, 19) and was calculated as follows:
Nb(inulin)/Ni(inulin) = exp (–k inulin * t) (Equation 2)
where k indicates inulin elimination rate and t indicates time. According to
our published model (16, 19), there are 2 possible physiological transport
routes of elimination of apoE and Aβ and of their complexes from brain ISF:
direct transport across the BBB into the bloodstream and elimination via ISF
bulk flow into the CSF and cervical lymphatics. In addition, cellular uptake
and subsequent processing (degradation) and proteolytic degradation within
the extracellular spaces may take place. The model allows for the possibility
10

that fractions of apoE or Aβ and/or of their complexes are retained in the
brain by binding to the cell surface receptors or other chaperone molecules
in the extracellular matrix, which may result either in their metabolism (degradation) or retention of undegraded material in the brain.
In a case of multiple time-point efflux series with departure of the later
time points from the linear efflux phase, i.e., more than 30 minutes for Aβ
peptides and more than 90 minutes for different apoE ligands, the fraction
of test tracer(s) remaining in the brain can be expressed as follows:
Nb(Aβ or apoE)/Ni(Aβ or apoE) = a1 + a2e–[k(1)]t (Equation 3)
where a1 = k2/(k1 + k2) and a2 = k1/(k1 + k2), e denotes exponential, and k1
and k2 denote the fractional coefficients of total efflux from the brain and
retention within the brain corrected for degradation, respectively, as reported (16, 17, 19). The fractional rate constant of Aβ or apoE efflux across the
BBB was calculated by using the fractional rate coefficient of total efflux of
the test Aβ or apoE tracer and the reference molecule (inulin) as follows:
k4 = k1 – k(inulin) (Equation 4)
The MLAB mathematical modeling system (Civilized Software Inc.) was
used to fit the compartmental model to the disappearance curves or percentage of recovery data with inverse square weightage. Kinetic constants
were obtained by a nonlinear regression curve fitting (GraphPad Prism
3.02; GraphPad Software).
In a case of a single-time point efflux series within the 90 minutes of the
linear efflux of different Aβ-apoE complexes, the fraction of Aβ-apoE that
remains undegraded in the brain at 90 minutes is related to the injected dose
of the Aβ-apoE tracer by the monoexponential equation as we reported (19):
Nb(Aβ-apoE)/Ni(Aβ-apoE) = exp(–k3 Aβ-apoE * t) (Equation 5)
where k3 is the total efflux rate of Aβ-apoE complex, Nb is the radioactivity
of undegraded Aβ-apoE complex remaining in the brain at the end of the
experiment, and Ni is the radioactivity injected into the brain ISF, i.e., TCA
precipitable 125I-radioactivity values corrected for degradation were used.
The fraction of Aβ-apoE complex cleared via ISF bulk flow was determined
by the clearance rate of simultaneously infused reference molecule inulin
using Equation 2, as above. The clearance rates of Aβ-apoE complexes across
the BBB, k4, were calculated as the difference between the total efflux rate
and efflux via ISF flow corrected for degradation, as reported (19):
k4 = k3 – k(inulin) (Equation 6)
Binding and internalization of apoE and Aβ test ligands by isolated brain capillaries. Brain microvessels from control and VLDLR–/– and LDLR–/– mice on
a C57BL/6 background were isolated, as we described (67).
Binding studies. For the binding studies, brain capillaries were incubated in 0.5 ml Eppendorf tubes (Protein LoBind Tube; Eppendorf) in the
assay buffer (mock CSF containing 1 mM sodium perchlorate to block
free iodide uptake) with 125I-labeled test ligands Aβ40 and Aβ42, apoE2
and apoE4 isoforms (lipid poor and lipidated), and different Aβ-apoE
complexes at a concentration of 2 nM at 4°C for 30 minutes, as reported
(17). After 30 minutes, the assay buffer containing unbound ligand was
removed and capillaries were washed in ice-cold assay buffer and counted.
Inhibition studies were performed with polyclonal goat receptor–specific
blocking antibodies (60 μg/ml) raised against the extracellular domain
of LDLR (AF2255; R&D Systems), VLDLR (AF2258; R&D Systems), and
LRP1 (N20; Santa Cruz Biotechnology Inc.). Binding of radiolabeled test
ligands to brain capillaries was corrected for the distribution of 14C-inulin
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(extracellular space marker) and nonspecific binding and determined as
the tissue to medium ratio: c.p.m. for TCA-precipitable 125I-radioactivity
(mg capillary protein)/c.p.m. for TCA-precipitable 125I-radioactivity (ml
medium) times ligand concentration in the medium (17).
Internalization studies. For the internalization studies, capillaries were
incubated in Eppendorf tubes in the assay buffer with 2 nM test ligands at
4°C for 30 minutes in the presence or absence of receptor-blocking antibodies, as described above. After 30 minutes, the assay buffer containing
unbound ligand was removed and capillaries were washed once with cold
assay buffer, resuspended in prewarmed (37°C) assay buffer, and placed
in a 37°C water bath. At predetermined times of 30 seconds and 1, 2.5, 5,
10, 15, and 30 minutes, Eppendorf tubes were quickly placed on ice and
incubated for 12 minutes with the ice-cold stop/strip solution to remove
ligand from the capillary abluminal cell surface. Capillaries were separated
by centrifugation and the capillary pellet was lysed with SDS buffer and
counted. The sum of internalized ligand plus the ligand associated with
the abluminal cell surface represented the amount of ligand available for
internalization (17). The fraction of ligand internalized at each time point
was plotted as described (32).
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